Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares of 455.92M shares rose 25.2% year over year, behind the +30.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +30.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +25.2% toward the trailing-twelve-month pace of +30.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
455.92M+1.3% QoQ
Last fiscal yearDec 2025
357.35M+23.3% YoY
LTMSep 2026
432.9M+30.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.2%——
1 year+23.3%——
3-year CAGR+30.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
357.35M USD
Year-over-year change
+23.3%
4-year CAGR
+23.5%

Weighted Avg Shares vs competitors

How IOVA compares with its peers on the latest reported figures

  • IOVA's LTM Sep 2026 weighted avg shares of 432.9M shares is the 3rd highest of the 11 companies compared; the peer median is 112.96M shares.
  • Its year-over-year change of +30.6% is the 3rd highest of 10, against a peer median of +3.0%.
  • Over three fiscal years its annual growth of +30.9% compares with a peer median of +8.4%.
IOVA Competitors Peer median
Weighted Avg Shares for IOVA and competitors
Company Period LTM YoY 3-year CAGR
IBRXImmunityBio, Inc.LTM Sep 20261.03B +20.6%+32.0%
GMABGenmab A/SLTM Jun 2026614.84M —-1.7%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026432.9M +30.6%+30.9%
BNTXBioNTech SELTM Jun 2026247.64M +3.0%-0.2%
LEGNLegend Biotech CorporationLTM Sep 2026185.87M +1.7%+5.0%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
IMNMImmunome, Inc.LTM Sep 2026106.83M +34.8%+93.1%
REPLReplimune Group, Inc.LTM Dec 202589.05M +21.7%+15.6%
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
IMCRImmunocore Holdings plcLTM Mar 202650.45M +0.8%+3.3%
Peer median (excluding IOVA) 112.96M+3.0%+8.4%

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.19M164.07M263.5M
Cost of Revenue0010.76M124M173.18M
Gross Profit00(9.57M)40.08M90.32M
Gross Margin——-804.5%24.4%34.3%
Research & Development259.04M294.78M344.08M282.34M300.27M
Selling, General & Admin83.66M104.1M106.92M153.02M152.32M
Operating Expenses342.7M398.88M450.99M435.35M488.53M
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
EBITDA(328.27M)(371.77M)(414.39M)(331.4M)(350.89M)
EBITDA Margin——-34851.9%-202.0%-133.2%
Operating Income(342.7M)(398.88M)(460.56M)(395.28M)(398.21M)
Operating Margin——-38735.0%-240.9%-151.1%
Interest Income451K2.99M13.04M20.27M10.31M
Interest Expense02.99M000
Other Income / Expenses451K2.99M13.04M20.27M5.16M
Income Before Tax(342.25M)(395.89M)(447.52M)(375.01M)(393.05M)
Pre-Tax Margin——-37638.0%-228.6%-149.2%
Income Tax Expense00(3.48M)(2.83M)(2.07M)
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Net Margin——-37345.4%-226.8%-148.4%
EPS (Basic)(2.23)(2.49)(1.89)(1.28)(1.09)
EPS (Diluted)(2.23)(2.49)(1.89)(1.28)(1.09)
Weighted Avg Shares153.41M159.26M235.13M289.88M357.35M
Weighted Avg Shares (Diluted)153.41M159.26M235.13M289.88M357.35M

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.